Amgen expands biosimilars programme

Biosimilares/Novedades | Posted 28/11/2014 post-comment0 Post your comment

Biologicals major Amgen is expanding its biosimilars portfolio to include nine different molecules.

DNA-Helix Serendipity V13K22

According to Mr Scott Foraker, Vice President and General Manager of biosimilars at Amgen, biosimilars are a good strategic fit for the company. They represent a compelling growth opportunity with the new portfolio of nine biosimilars having the potential to deliver more than US$3 billion in annual revenues.

Amgen is already developing biosimilars for cancer treatments: Avastin (bevacizumab), Herceptin (trastuzumab), Rituxan/MabThera (rituximab) from Roche and Erbitux (cetuximab) from Eli Lilly; for arthritis and Crohn’s disease treatments: Humira (adalimumab) from AbbVie and Remicade (infliximab) from Johnson & Johnson. In addition to the existing six biosimilar programmes [2], Amgen has also initiated three additional biosimilar programmes, bringing its total biosimilar programmes to nine.

Amgen is carrying out a global phase III clinical trial to evaluate the pharmacokinetic similarity of its biosimilar rituximab (ABP 798) compared to Roche’s blockbuster arthritis/non-Hodgkin’s lymphoma drug MabThera/Rituxan (rituximab) [1]. The company has reported positive results from a phase III study of its adalimumab biosimilar (ABP 501) compared with Humira (adalimumab) [3].

Amgen expects to launch its first biosimilar in 2017, followed by four others through 2019.

Related articles
Biosimilars of adalimumab

Sandoz advances biosimilars pipeline

1.   GaBI Online - Generics and Biosimilars Initiative. Amgen starts phase III trial for biosimilar rituximab []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Nov 28]. Available from: 
2.   Derbyshire M. Biosimilars collaboration at Amgen and Actavis. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(3):155-6. doi:10.5639/gabij.2014.0303.035
3.   GaBI Online - Generics and Biosimilars Initiative. Phase III study of biosimilar adalimumab meets primary endpoint []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Nov 28]. Available from: 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.

Source: Amgen

comment icon Comments (0)
Post your comment
Related content
La FDA aprueba el biosimilar de bevacizumab Avzivi
Cancer Cell V13I20
Biosimilares/Novedades Posted 30/01/2024
La FDA aprueba el biosimilar pegfilgrastim Stimufend
Biosimilares/Novedades Posted 07/10/2022
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010